Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Dan Hamilton who wrote (922)	6/28/1999 7:40:00 PM
From: Michael Brody	Read Replies (1) \| Respond to of 2344

All, Isn't anyone just a little bit puzzled as to why BIOM sits at it's current levels (considering its pipeline and stage of development) while IMCL is over 20 ? Would really appreciate thoughtful comments on this. We have spoken about lack of press coverage but does IMCL really get THAT much more coverage ? Too much dilution ? Forefront of a new approach to the treatment of Cancer ? Mononclonal antibody therapy works (Herceptin, now IMCL C225). There would seem to be plenty in BIOM's approach to stir the imagination. Am I missing a factor that I should know about ??? Things do not seem to add up. Concerned Long. I guess that NY Times article has fallen into a Black Hole ?